• Disease burden of varicella versus other vaccine-preventable diseases before introduction of vaccination into the national immunisation programme in the Netherlands.

      van Lier, Alies; de Gier, Brechje; McDonald, Scott A; Mangen, Marie-Josée J; van Wijhe, Maarten; Sanders, Elisabeth A M; Kretzschmar, Mirjam E; van Vliet, Hans; de Melker, Hester E (2019-05-01)
    • Estimating the Population-Level Effectiveness of Vaccination Programs in the Netherlands.

      van Wijhe, Maarten; McDonald, Scott A; de Melker, Hester E; Postma, Maarten J; Wallinga, Jacco (2018-03)
      There are few estimates of the effectiveness of long-standing vaccination programs in developed countries. To fill this gap, we investigate the direct and indirect effectiveness of childhood vaccination programs on mortality at the population level in the Netherlands.
    • Respiratory Syncytial Virus-Associated Hospital Admissions in Children Younger Than 5 Years in 7 European Countries Using Routinely Collected Datasets.

      Reeves, Rachel M; van Wijhe, Maarten; Tong, Sabine; Lehtonen, Toni; Stona, Luca; Teirlinck, Anne C; Fernandez, Liliana Vazquez; Li, You; Giaquinto, Carlo; Fischer, Thea Kølsen; et al. (2020-08-20)
    • Trends in governmental expenditure on vaccination programmes in the Netherlands, a historical analysis.

      van Wijhe, Maarten; de Boer, Pieter T; de Jong, Herman J; van Vliet, Hans; Wallinga, Jacco; Postma, Maarten J (2019-09-10)
    • Vaccinatieprogramma's in Nederland ; Impact op het aantal ziektegevallen.

      Tulen, Anna D; van Wijhe, Maarten; Korthals Altes, Hester; McDonald, Scott A; de Melker, Hester E; Postma, Maarten J; Wallinga, Jacco (2018-09-20)
      To quantify the impact of long-standing vaccination programmes on notified cases in the Netherlands. Estimates based on model projections of historical morbidity data. We collected and digitised previously unavailable monthly case notifications of diphtheria, poliomyelitis, mumps and rubella in the Netherlands over the period 1919-2015. Poisson regression models accounting for seasonality, multi-year cycles, secular trends and auto-correlation were fit to pre-vaccination periods. Cases averted were calculated as the difference between observed and expected cases based on model projections. In the first 13 years of mass vaccinations, case notifications declined rapidly with 18,900 (95%-CI: 12,000-28,600) notified cases of diphtheria averted, 5100 (95%-CI: 2200-13,500) cases of poliomyelitis, and 1800 (95%-CI: 1000-3200) cases of mumps. Vaccination of 11-year-old girls against rubella averted 13700 (95%-CI: 1400-38,300) cases, while universal rubella vaccination averted 700 (95%-CI: 80-2300) cases.
    • Years of life lost due to influenza-attributable mortality in older adults in the Netherlands: a competing risks approach.

      McDonald, Scott A; van Wijhe, Maarten; van Asten, Liselotte; van der Hoek, Wim; Wallinga, Jacco (2018-02-06)
      We estimated the influenza mortality burden in adults 60 years of age and older in the Netherlands in terms of years of life lost, taking into account competing mortality risks. Weekly laboratory surveillance data for influenza and other respiratory pathogens and weekly extreme temperature served as covariates in Poisson regression models fitted to weekly age-group specific mortality data for the period 1999/2000 through 2012/13. Burden for age-groups 60-64 through 85-89 years was computed as years of life lost before age 90 (YLL90) using restricted mean lifetimes survival analysis and accounting for competing risks. Influenza-attributable mortality burden was greatest for persons aged 80-84 years, at 914 YLL90 per 100,000 persons (95% uncertainty interval:867, 963), followed by 85-89 years (787 YLL90/100,000; 95% uncertainty interval:741, 834). Ignoring competing mortality risks in the computation of influenza-attributable YLL90 would lead to substantial over-estimation of burden, from 3.5% for 60-64 years to 82% for persons aged 80-89 years at death. Failure to account for competing mortality risks has implications for accuracy of disease burden estimates, especially among persons aged 80 years and older. As the mortality burden borne by the elderly is notably high, prevention initiatives may benefit from being redesigned to more effectively prevent infection in the oldest age-groups.